Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PTLA's Cash to Debt is ranked higher than
72% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. PTLA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PTLA' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6431
N/A
No Debt
Equity to Asset 0.86
PTLA's Equity to Asset is ranked higher than
74% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PTLA: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
PTLA' s 10-Year Equity to Asset Range
Min: -1.31  Med: 0.84 Max: 0.91
Current: 0.86
-1.31
0.91
Interest Coverage No Debt
PTLA's Interest Coverage is ranked lower than
62% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTLA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTLA' s 10-Year Interest Coverage Range
Min: 946.14  Med: 10000.00 Max: 9999.99
Current: No Debt
946.14
9999.99
F-Score: 4
Z-Score: 19.66
M-Score: -3.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1592.07
PTLA's Operating margin (%) is ranked lower than
82% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. PTLA: -1592.07 )
Ranked among companies with meaningful Operating margin (%) only.
PTLA' s 10-Year Operating margin (%) Range
Min: -1429.26  Med: -53.18 Max: 25.46
Current: -1592.07
-1429.26
25.46
Net-margin (%) -1594.84
PTLA's Net-margin (%) is ranked lower than
83% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. PTLA: -1594.84 )
Ranked among companies with meaningful Net-margin (%) only.
PTLA' s 10-Year Net-margin (%) Range
Min: -1424.68  Med: -57.47 Max: 25.61
Current: -1594.84
-1424.68
25.61
ROE (%) -51.55
PTLA's ROE (%) is ranked lower than
63% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. PTLA: -51.55 )
Ranked among companies with meaningful ROE (%) only.
PTLA' s 10-Year ROE (%) Range
Min: -159.12  Med: -100.85 Max: -42.58
Current: -51.55
-159.12
-42.58
ROA (%) -42.67
PTLA's ROA (%) is ranked lower than
64% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. PTLA: -42.67 )
Ranked among companies with meaningful ROA (%) only.
PTLA' s 10-Year ROA (%) Range
Min: -36.95  Med: -14.32 Max: 20.67
Current: -42.67
-36.95
20.67
ROC (Joel Greenblatt) (%) -5359.13
PTLA's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. PTLA: -5359.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTLA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5117.78  Med: -1373.03 Max: 1029.06
Current: -5359.13
-5117.78
1029.06
» PTLA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PTLA Guru Trades in

Q3 2014

PTLA Guru Trades in Q3 2014

Steven Cohen 160,000 sh (New)
» More
Q4 2014

PTLA Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
Q1 2015

PTLA Guru Trades in Q1 2015

Ken Fisher 80,300 sh (New)
Jim Simons 59,950 sh (New)
Paul Tudor Jones 6,016 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.68
PTLA's P/B is ranked lower than
57% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. PTLA: 5.68 )
Ranked among companies with meaningful P/B only.
PTLA' s 10-Year P/B Range
Min: 3.07  Med: 4.25 Max: 5.69
Current: 5.68
3.07
5.69
P/S 215.17
PTLA's P/S is ranked lower than
87% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. PTLA: 215.17 )
Ranked among companies with meaningful P/S only.
PTLA' s 10-Year P/S Range
Min: 5.28  Med: 97.24 Max: 215.56
Current: 215.17
5.28
215.56
EV-to-EBIT -12.94
PTLA's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. PTLA: -12.94 )
Ranked among companies with meaningful EV-to-EBIT only.
PTLA' s 10-Year EV-to-EBIT Range
Min: -12.2  Med: -8.10 Max: -1.3
Current: -12.94
-12.2
-1.3
Current Ratio 9.89
PTLA's Current Ratio is ranked higher than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. PTLA: 9.89 )
Ranked among companies with meaningful Current Ratio only.
PTLA' s 10-Year Current Ratio Range
Min: 5.12  Med: 7.49 Max: 10.67
Current: 9.89
5.12
10.67
Quick Ratio 9.89
PTLA's Quick Ratio is ranked higher than
75% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PTLA: 9.89 )
Ranked among companies with meaningful Quick Ratio only.
PTLA' s 10-Year Quick Ratio Range
Min: 5.12  Med: 7.49 Max: 10.67
Current: 9.89
5.12
10.67
Days Sales Outstanding 0.46
PTLA's Days Sales Outstanding is ranked higher than
99% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. PTLA: 0.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTLA' s 10-Year Days Sales Outstanding Range
Min: 2.16  Med: 3.91 Max: 10.71
Current: 0.46
2.16
10.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.36
PTLA's Price/Net Cash is ranked higher than
58% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. PTLA: 7.36 )
Ranked among companies with meaningful Price/Net Cash only.
PTLA' s 10-Year Price/Net Cash Range
Min: 4.4  Med: 5.91 Max: 6.87
Current: 7.36
4.4
6.87
Price/Net Current Asset Value 7.10
PTLA's Price/Net Current Asset Value is ranked higher than
54% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. PTLA: 7.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTLA' s 10-Year Price/Net Current Asset Value Range
Min: 4.33  Med: 5.74 Max: 6.68
Current: 7.1
4.33
6.68
Price/Tangible Book 5.70
PTLA's Price/Tangible Book is ranked higher than
52% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. PTLA: 5.70 )
Ranked among companies with meaningful Price/Tangible Book only.
PTLA' s 10-Year Price/Tangible Book Range
Min: 3.56  Med: 4.38 Max: 5.01
Current: 5.7
3.56
5.01
Price/Median PS Value 2.14
PTLA's Price/Median PS Value is ranked lower than
76% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. PTLA: 2.14 )
Ranked among companies with meaningful Price/Median PS Value only.
PTLA' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 0.93 Max: 1.77
Current: 2.14
0.07
1.77
Earnings Yield (Greenblatt) (%) -7.65
PTLA's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. PTLA: -7.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTLA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -12.2  Med: 0.00 Max: 0
Current: -7.65
-12.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PP.Germany,
Portola Pharmaceuticals Inc was incorporated in Delaware in September 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Its two programs address significant unmet medical needs in the areas of thrombosis or blood clots. Its compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. The Company's current product candidates in development includes: Betrixaban, PRT4445, PRT2070, and PRT2607. Betrixaban is a novel oral once-daily inhibitor of Factor Xa in development for extended duration VTE prophylaxis in acute medically ill patients for up to 35 days. PRT4445 is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. PRT2070 is an orally available, potent inhibitor of Syk and JAK. PRT2607 is an orally available, potent and selective inhibitor of Syk. The Company faces competition from large and small pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions and others.
» More Articles for PTLA

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 

More From Other Websites
Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly... Jun 24 2015
Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly... Jun 24 2015
Why Does Credit Suisse Like Portola Pharma? Jun 24 2015
Portola, Bristol-Myers and Pfizer Report Encouraging Data - Analyst Blog Jun 23 2015
Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3... Jun 22 2015
Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A™... Jun 22 2015
Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3... Jun 22 2015
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 18 2015
Bellicum Pharmaceuticals Slumps: BLCM Falls 9.6% in Session - Tale of the Tape Jun 17 2015
Marinus Pharmaceuticals (MRNS) in Focus: Stock Tumbles 8.4% - Tale of the Tape Jun 17 2015
Edited Transcript of PTLA presentation 12-May-15 5:00pm GMT Jun 17 2015
Sage Therapeutics (SAGE) in Focus: Stock Tumbles 8.7% - Tale of the Tape Jun 16 2015
Edited Transcript of PTLA earnings conference call or presentation 6-May-15 8:30pm GMT Jun 16 2015
Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief... Jun 15 2015
Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief... Jun 15 2015
Portola Pharma, NetGear, Target, J. C. Penney and American Eagle Outfitters highlighted as Zacks... Jun 11 2015
Portola Pharmaceuticals (PTLA) Shares March Higher, Can It Continue? - Tale of the Tape Jun 11 2015
Edited Transcript of PTLA presentation 10-Jun-15 3:00pm GMT Jun 11 2015
Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International... Jun 09 2015
Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International... Jun 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK